Table 1

Baseline characteristics of patients with biopsy-proven NAFLD

Serum ALT level (U/L)
Overall
(N=345)
abnALT group
(n=240)
nALT group
(n=105)
P value
Clinical parameters
 Female sex, n (%)83 (24.1)45 (18.8)38 (36.2)0.001
 Age, years40.2±12.537.8±12.145.5±11.6<0.001
 WCC, ×109/L6.22±1.506.41±1.605.80±1.12<0.001
 RBC, ×1012/L5.01±0.505.11±0.504.78±0.44<0.001
 PLT, ×109/L245.48±57.72243.62±58.69249.72±55.500.367
 MPV, fL10.92±0.9910.95±1.0210.87±0.920.506
 SDPV, fL13.80±2.7713.94±3.0213.48±2.090.160
 Albumin, g/L46.76±3.7447.34±3.1945.43±4.50<0.001
 ALT, U/L82.47±77.04106.43±81.3827.70±7.77<0.001
 AST, U/L49.08±33.5859.28±35.5025.77±6.75<0.001
 ALP, U/L88.43±39.1790.38±35.9483.96±45.570.161
 GGT, U/L75.79±99.3989.71±114.3043.98±34.37<0.001
 Fasting glucose, mmol/L5.60±1.425.47±1.245.91±1.740.007
 BUN, mmol/L4.83±1.284.80±1.254.90±1.340.505
 Creatinine, μmol/L67.94±14.4968.72±14.1266.17±15.220.133
 Uric acid, μmol/L403.35±105.20420.57±106.75364.00±90.37<0.001
 Total cholesterol, mmol/L5.05±1.115.14±1.094.84±1.150.023
 Triglycerides, mmol/L2.30±1.412.31±1.282.27±1.690.774
 HDL cholesterol, mmol/L1.01±0.231.00±0.231.04±0.230.232
 LDL cholesterol, mmol/L3.08±0.923.18±0.892.86±0.950.002
 GP73, ng/mL80.96±40.0585.55±43.0270.45±29.880.001
 CK18-M30, U/L354.21±633.71457.84±726.10102.21±88.79<0.001
 Zinc, μmol/L18.75±4.0018.98±4.0018.24±3.980.169
 Thyroxine, nmol/L105.69±18.49105.59±18.20105.93±19.240.874
 HbA1c, %6.03±1.275.92±1.126.28±1.530.014
 Fasting insulin, pmol/L151.54±216.56159.67±238.69132.76±153.190.290
 HOMA-IR5.97±10.155.96±10.355.99±9.700.980
 AFP, ng/mL2.99±1.423.01±1.342.94±1.600.674
 Ferritin, μg/L347.71±242.07393.36±252.50243.25±178.13<0.001
 Type III procollagen, ng/mL21.38±19.7422.80±23.4218.21±4.770.049
 Type IV collagen, ng/mL20.57±9.5721.73±10.8718.00±4.800.001
 Hyaluronic acid, ng/mL48.26±39.8948.49±46.3047.74±19.220.874
Comorbid diseases, n (%)
 Diabetes104 (30.1)66 (27.5)38 (36.2)0.136
 Metabolic syndrome199 (60.3)144 (62.9)55 (54.5)0.187
 Hypertension111 (32.2)74 (30.8)37 (35.2)0.496
 Dyslipidemia313 (91.5)221 (92.9)92 (88.5)0.258
 Hyperuricemia131 (38.0)107 (44.6)24 (22.9)<0.001
 Obesity
BMI 25–29.9 kg/m2
190 (55.1)143 (59.6)47 (44.8)0.015
 Obesity
 BMI ≥30 kg/m2
48 (14.0)37 (15.5)11 (10.5)0.287
Anthropometry
 Waist circumference, cm92.25±8.7093.30±8.4489.87±8.850.001
 Hip circumference, cm99.69±7.46100.63±7.2797.57±7.500.001
 BMI, kg/m226.93±4.2027.31±4.4926.05±3.330.010
Liver histology
 NASH, n (%)240 (69.6)187 (77.9)53 (50.5)<0.001
 Steatosis, n (%)<0.001
  1142 (41.2)67 (27.9)75 (71.4)
  291 (26.4)73 (30.4)18 (17.1)
  3112 (32.5)100 (41.7)12 (11.4)
 Hepatocyte ballooning, n (%)0.272
  013 (3.8)8 (3.3)5 (4.8)
  1182 (52.8)121 (50.4)61 (58.1)
  2150 (43.5)111 (46.2)39 (37.1)
 Lobular inflammation, n (%)0.004
  021 (6.1)11 (4.6)10 (9.5)
  1249 (72.2)165 (68.8)84 (80.0)
  270 (20.3)60 (25.0)10 (9.5)
  35 (1.4)4 (1.7)1 (1.0)
 Fibrosis, n (%)0.059
  0111 (32.3)69 (28.9)42 (40.0)
  1161 (46.8)124 (51.9)37 (35.2)
  255 (16.0)34 (14.2)21 (20.0)
  316 (4.7)11 (4.6)5 (4.8)
  41 (0.3)1 (0.4)0 (0.0)
  • Continuous variables are presented as mean±SD; categorical variables are presented as n (%).

  • P values <0.05 are in bold.

  • abnALT, ALT above the upper limit of normal; AFP, alpha-fetoprotein; ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; BUN, blood urea nitrogen; CK18-M30, cytokeratin-18 M30 fragments; GGT, gamma-glutamyl transferase; GP73, Golgi protein 73; HbA1c, hemoglobin A1c; HDL, high-density lipoprotein; HOMA-IR, homeostasis model assessment of insulin resistance; LDL, low-density lipoprotein; MPV, mean platelet volume; NAFLD, non-alcoholic fatty liver disease; nALT, normal ALT; NASH, non-alcoholic steatohepatitis; PLT, platelet; RBC, red blood cell; SDPV, SD of platelet volume; WCC, white cell count.